# Developmental Funds

> **NIH NIH P30** · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $322,578

## Abstract

ABSTRACT, Developmental Funds
Developmental funds are a critical component of the budget used to invest in new innovations, valuable shared
resources, and key areas of research. In the coming project period, the IUSCC will use developmental funds to
address the following aims: 1: To identify the most promising and innovative pilot projects in cancer
research. Cultivate and catalyze new research collaborations and teams around the strengths of our center
through continued investment in our pilot funding program. Priority is given to the most innovative projects that
could lead to future NCI-sponsored research that leads to reduced incidence and mortality rates or increased
quality of life for cancer patients in Indiana and beyond; 2: To facilitate collaborative research projects and
how they are conducted to maximize their success. All award recipients are mentored and monitored through
the novel IUSCC Translational Research Acceleration Collaboration (ITRAC) Project Management Process.
Special emphasis is made to optimize use of IUSCC Cores and to encourage collaborations towards multi-PI
grant proposals; 3: To conduct rigorous monitoring and evaluation of all projects. Once approved for
funding, all projects are monitored and evaluated using the ITRAC process of IUSCC. This process has been
used for monitoring and evaluating all IUSCC Pilot Funded Projects since 2006. Written progress reports are
submitted to the IUSCC leadership council (LC) and executive committee (EC) for review of progress. In addition,
the EAB and IAB reviews the progress at their annual meetings; and 4: To develop the Translational Research
Core (TRC). The TRC has been developed to assist investigators, both clinical and basic scientists, with
developing and performing in-house drug development of Phase I clinical trials. The TRC also performs
correlative biological assays needed to validate mechanism(s) of action of candidate drugs/therapies and to
develop and test new hypotheses.

## Key facts

- **NIH application ID:** 10247620
- **Project number:** 5P30CA082709-22
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Mark R. Kelley
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $322,578
- **Award type:** 5
- **Project period:** 1999-09-22 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10247620

## Citation

> US National Institutes of Health, RePORTER application 10247620, Developmental Funds (5P30CA082709-22). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10247620. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*